HER2 ITH was determined to be a strong predictor of resistance to a dual-HER2-targeted therapy regimen (T-DM1 plus Pertuzumab), with no patients with cancers classified as heterogeneous experiencing a pCR30. The gene discussed is ERBB2; the disease is cancer.